AbbVie is joining its fellow Big Pharma competitors and jumping into the Treg space.
In a collaboration deal announced early Monday morning, the Chicago-based pharma company said it would be teaming up with private biotech Cugene to advance a single Treg program targeting IL-2. AbbVie is shelling out $48.5 million...
